Intended for healthcare professionals

Latest dermatology news

 

Regeneron’s Libtayo shows promise in phase 3 high-risk skin cancer trial

Cutaneous squamous cell carcinoma affects approximately 1.8 million people in the US every year

23 Jan 2025

Bristol Myers Squibb shares promising phase 3 results for Sotyktu in psoriatic arthritis

More than eight million people in the US are living with psoriasis, and up to 30% will develop psoriatic arthritis

16 Jan 2025

FDA grants approval to Organon’s Vtama cream in atopic dermatitis

The inflammatory skin disease affects up to 10% of adults and 20% of children globally

09 Jan 2025

EMA committee recommends Galderma’s nemolizumab for prurigo nodularis and atopic dermatitis

The European Commission will now consider the recommendations as it makes its decision on the drug

02 Jan 2025

LEO Pharma receives MHRA approval for Anzupgo cream in chronic hand eczema

Approximately 70% of patients with severe cases of the condition have reported problems performing everyday activities

19 Dec 2024

Galderma shares positive phase 3 data for nemolizumab in prurigo nodularis

Up to 181,000 people are living with the chronic skin condition in the US

11 Dec 2024

J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis trial

The immune-mediated disease affects more than 125 million people globally

05 Dec 2024

UCB’s Bimzelx approved by FDA to treat hidradenitis suppurativa

The drug is already approved in the US for conditions including plaque psoriasis

28 Nov 2024

LEO Pharma announces long-term results for Adbry in atopic dermatitis

The phase 3 study evaluated the drug for up to five years in patients with moderate-to-severe cases

21 Nov 2024

FDA approves Journey Medical’s Emrosi for adults with rosacea

More than 16 million people in the US are affected by the long-term inflammatory skin condition

13 Nov 2024
12345678910...